Department of Public Health and Pediatrics, University of Torino, Torino, Italy.
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
Oncologist. 2019 Sep;24(9):e953-e959. doi: 10.1634/theoncologist.2018-0281. Epub 2019 Feb 12.
Peripherally inserted central catheters (PICCs) are central venous catheters (CVCs) that are commonly used in onco-hematologic settings for chemotherapy administration. As there is insufficient evidence to recommend a specific CVC for chemotherapy administration, we aimed to ascertain PICC-related adverse events (AEs) and identify independent predictors of PICC removal in patients with cancer receiving chemotherapy.
Information on adult patients with cancer with a PICC inserted for chemotherapy administration between September 2007 and December 2014 was extracted from six hospital databases. The primary outcome was PICC removal due to PICC-related AEs (occlusion, infection, or symptomatic thrombosis). Independent predictors of PICC removal were identified using a multivariate Cox regression model.
Among the 2,477 included patients, 419 PICC-related AEs (16.9%; 1.09 AEs per 1,000 PICC-days) were reported. AEs increased when PICC was inserted at the brachial site (hazard ratio [HR], 1.37; 95% confidence interval [CI], 1.02-1.84) and with open systems (HR, 1.89; 95% CI, 1.24-2.88) and decreased in older men (HR, 0.63; 95% CI, 0.49-0.81).
Use of PICC for chemotherapy administration was associated with a low all-AEs rate. The basilic vein was the safer site, and valved systems had fewer AEs than open systems. More research is needed to explore the interaction between AEs, sex, and age.
These findings provide clinicians with evidence that peripherally inserted central catheters PICCs) are safe for chemotherapy administration. They also suggest that clinicians should limit the use of open systems when long chemotherapy regimens are scheduled. Moreover, alternatives to PICCs should be considered when administering chemotherapy to young men.
经外周静脉置入的中心静脉导管(PICC)是一种中心静脉导管(CVC),常用于肿瘤血液病患者进行化疗。由于没有足够的证据推荐特定的 CVC 用于化疗,我们旨在确定 PICC 相关不良事件(AE),并确定接受化疗的癌症患者中 PICC 拔除的独立预测因素。
从六个医院数据库中提取了 2007 年 9 月至 2014 年 12 月期间接受化疗的成年癌症患者的 PICC 置管信息。主要结局是由于 PICC 相关 AE(闭塞、感染或有症状的血栓形成)而拔除 PICC。使用多变量 Cox 回归模型确定 PICC 拔除的独立预测因素。
在纳入的 2477 例患者中,报告了 419 例 PICC 相关 AE(16.9%;每 1000 个 PICC 天发生 1.09 例 AE)。当 PICC 在臂部插入时(风险比 [HR],1.37;95%置信区间 [CI],1.02-1.84)和使用开放式系统时(HR,1.89;95% CI,1.24-2.88),AE 增加,而在老年男性中(HR,0.63;95% CI,0.49-0.81)则减少。
使用 PICC 进行化疗与较低的全 AE 发生率相关。贵要静脉是更安全的部位,而带瓣系统的 AE 少于开放式系统。需要更多的研究来探索 AE、性别和年龄之间的相互作用。
这些发现为临床医生提供了证据,表明经外周静脉置入的中心静脉导管(PICC)可安全用于化疗。它们还表明,当计划进行长期化疗方案时,临床医生应限制使用开放式系统。此外,在为年轻男性进行化疗时,应考虑替代 PICC。